Summary
In order to assess mechanisms predictive of response or resistance to intense neoadjuvant therapy, we performed automated immunohistochemistry on targeted biopsies from patients with intermediate or high risk prostate cancer. All biopsy were stained with H&E or antibodies against: p53, PTEN, AR, PSA, GR, Ki67, SYP and PIN4-cocktail (p63+CK5+K18+AMACR). We further performed automated immunohistochemistry on whole mount radical prostatectomy tissues containing residual tumor. RP tissues were stained with H&E or antibodies against: PTEN, AR, AR-V7, PSA, PSMA, GR, Ki67, SYP and PIN4-cocktail (p63+CK5+K18+AMACR), with some slides stained for other markers of residual tumor, to include NKX3.1 and CAM5.2. Slides were scanned at 20x magnification. For each patient, response to intense neoadjuvant therapy is known. As biopsies were targeted to MRI-visible lesions, lesion-level response to therapy is also known. For each biopsy, gene expression profile by RNA-seq and exome sequencing were performed on tumor tissue laser capture microdissected from serial sections. Up to 4 foci were dissected per biopsy. Whole-genome of germline DNA from each patient was also performed.Exome and gene expression data corresponding to pre-treatment biopsy tissues has been deposited in dbGaP and GEO. Genome, exome and expression data from post-treatment radical prostatectomy tissues is underway. As slides were stained using an automated slide stainer, this is a rich resource for performing data mining for assessing histogenomic correlates or signatures of treatment response or resistance. Our goal is also to eventually deposit the pre- and post-treatment mpMRI data from this cohort that matches the tissue, but those data are not ready for deposit and thus cannot be deposited at this time.
Acknowledgements
The authors gratefully acknowledge the patients and the families of patients who contributed to this study.
Data Access
Data Type | Download all or Query/Filter |
---|---|
Tissue Biopsy Slide Images (TIFF, 1.4 TB) | |
Clinical data (XLS) |
Click the Versions tab for more info about data releases.
Please contact help@cancerimagingarchive.net with any questions regarding usage.
Detailed Description
Image Statistics | |
---|---|
Modalities | Pathology |
Number of Patients | 37 |
Number of Images | 1401 |
Images Size (TB) | 1.4 |
Citations & Data Usage Policy
Data Citation
Draft version: 10.7937/tcia.jhqd-fr46
Publication Citation
Wilkinson, S., Ye, H., Karzai, F., Harmon, S. A., Terrigino, N. T., VanderWeele, D. J., Bright, J. R., Atway, R., Trostel, S. Y., Carrabba, N. V., Whitlock, N. C., Walker, S. M., Lis, R. T., Abdul Sater, H., Capaldo, B. J., Madan, R. A., Gulley, J. L., Chun, G., Merino, M. J., … Sowalsky, A. G. (2021). Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. European Urology. https://doi.org/10.1016/j.eururo.2021.03.009
TCIA Citation
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. DOI: 10.1007/s10278-013-9622-7
Other Publications Using This Data
TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you'd like to add please contact the TCIA Helpdesk.
Version 1 (Current): Updated 2021/10/08
Data Type | Download all or Query/Filter |
---|---|
Tissue Biopsy Slide Images (TIFF, 1.4 TB) | |
Clinical Data (XLS) |